Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A narrative review of facilitators and barriers to smoking cessation and tobacco-dependence treatment in patients with tuberculosis in low- and middle-income countries

K. Zvolska, A. Pankova, I. Nohavova, R. Huque, H. Elsey, M. Boeckmann, A. Sheikh, K. Siddiqi, E. Kralikova,

. 2020 ; 18 (-) : 67. [pub] 20200806

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021855

INTRODUCTION: Smoking is a substantial cause of premature death in patients with tuberculosis (TB), particularly in low- and middle-income countries (LMICs) with high TB prevalence. The importance of incorporating smoking cessation and tobacco-dependence treatment (TDT) into TB care is highlighted in the most recent TB care guidelines. Our objective is to identify the likely key facilitators of and barriers to smoking cessation for patients with TB in LMICs. METHODS: A systematic search of studies with English-language abstracts published between January 2000 and May 2019 was undertaken in the EMBASE, MEDLINE, EBSCO, ProQuest, Cochrane and Web of Science databases. Data extraction was followed by study-quality assessment and a descriptive and narrative synthesis of findings. RESULTS: Out of 267 potentially eligible articles, 36 satisfied the inclusion criteria. Methodological quality of non-randomized studies was variable; low risk of bias was assessed in most randomized controlled studies. Identified facilitators included brief, repeated interventions, personalized behavioural counselling, offer of pharmacotherapy, smoke-free homes and a reasonable awareness of smoking-associated risks. Barriers included craving for a cigarette, low level of education, unemployment, easy access to tobacco in the hospital setting, lack of knowledge about quit strategies, and limited space and privacy at the clinics. Findings show that the risk of smoking relapse could be reduced through consistent follow-up upon completion of TB therapy and receiving a disease-specific smoking cessation message. CONCLUSIONS: Raising awareness of smoking-related health risks in patients with TB and implementing guideline-recommended standardized TDT within national TB programmes could increase smoking cessation rates in this high-risk population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021855
003      
CZ-PrNML
005      
20210208144035.0
007      
ta
008      
201125s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.18332/tid/125195 $2 doi
035    __
$a (PubMed)32818030
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Zvolska, Kamila $u Centre for Tobacco-Dependent, Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic.
245    12
$a A narrative review of facilitators and barriers to smoking cessation and tobacco-dependence treatment in patients with tuberculosis in low- and middle-income countries / $c K. Zvolska, A. Pankova, I. Nohavova, R. Huque, H. Elsey, M. Boeckmann, A. Sheikh, K. Siddiqi, E. Kralikova,
520    9_
$a INTRODUCTION: Smoking is a substantial cause of premature death in patients with tuberculosis (TB), particularly in low- and middle-income countries (LMICs) with high TB prevalence. The importance of incorporating smoking cessation and tobacco-dependence treatment (TDT) into TB care is highlighted in the most recent TB care guidelines. Our objective is to identify the likely key facilitators of and barriers to smoking cessation for patients with TB in LMICs. METHODS: A systematic search of studies with English-language abstracts published between January 2000 and May 2019 was undertaken in the EMBASE, MEDLINE, EBSCO, ProQuest, Cochrane and Web of Science databases. Data extraction was followed by study-quality assessment and a descriptive and narrative synthesis of findings. RESULTS: Out of 267 potentially eligible articles, 36 satisfied the inclusion criteria. Methodological quality of non-randomized studies was variable; low risk of bias was assessed in most randomized controlled studies. Identified facilitators included brief, repeated interventions, personalized behavioural counselling, offer of pharmacotherapy, smoke-free homes and a reasonable awareness of smoking-associated risks. Barriers included craving for a cigarette, low level of education, unemployment, easy access to tobacco in the hospital setting, lack of knowledge about quit strategies, and limited space and privacy at the clinics. Findings show that the risk of smoking relapse could be reduced through consistent follow-up upon completion of TB therapy and receiving a disease-specific smoking cessation message. CONCLUSIONS: Raising awareness of smoking-related health risks in patients with TB and implementing guideline-recommended standardized TDT within national TB programmes could increase smoking cessation rates in this high-risk population.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Pankova, Alexandra $u Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Tobacco-Dependent, Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Nohavova, Iveta $u Centre for Tobacco-Dependent, Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic. Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Huque, Rumana $u Department of Research and Development, ARK Foundation, Dhaka, Bangladesh.
700    1_
$a Elsey, Helen $u Department of Health Sciences, University of York, York, United Kingdom.
700    1_
$a Boeckmann, Melanie $u Department of Environment and Health, School of Public Health, Bielefeld University, Bielefeld, Germany. Department of Health Sciences, University of York, York, United Kingdom. Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
700    1_
$a Sheikh, Aziz $u Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
700    1_
$a Siddiqi, Kamran $u Department of Health Sciences, University of York, York, United Kingdom.
700    1_
$a Kralikova, Eva $u Centre for Tobacco-Dependent, Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic. Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00165388 $t Tobacco induced diseases $x 1617-9625 $g Roč. 18, č. - (2020), s. 67
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32818030 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20210208144034 $b ABA008
999    __
$a ind $b bmc $g 1591564 $s 1112527
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 18 $c - $d 67 $e 20200806 $i 1617-9625 $m Tobacco induced diseases $n Tob. induc. dis. $x MED00165388
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace